DNTH
Price
$18.85
Change
+$0.47 (+2.56%)
Updated
Jul 3 closing price
Capitalization
606.22M
ZVRA
Price
$9.74
Change
+$0.33 (+3.51%)
Updated
Jul 3 closing price
Capitalization
532.58M
43 days until earnings call
Interact to see
Advertisement

DNTH vs ZVRA

Header iconDNTH vs ZVRA Comparison
Open Charts DNTH vs ZVRABanner chart's image
Dianthus Therapeutics
Price$18.85
Change+$0.47 (+2.56%)
Volume$101.6K
Capitalization606.22M
Zevra Therapeutics
Price$9.74
Change+$0.33 (+3.51%)
Volume$1.18M
Capitalization532.58M
DNTH vs ZVRA Comparison Chart in %
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. ZVRA commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Hold and ZVRA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (DNTH: $18.85 vs. ZVRA: $9.41)
Brand notoriety: DNTH and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 37% vs. ZVRA: 1%
Market capitalization -- DNTH: $606.22M vs. ZVRA: $532.58M
DNTH [@Biotechnology] is valued at $606.22M. ZVRA’s [@Biotechnology] market capitalization is $532.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than DNTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 3 TA indicator(s) are bullish while ZVRA’s TA Score has 5 bullish TA indicator(s).

  • DNTH’s TA Score: 3 bullish, 5 bearish.
  • ZVRA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than DNTH.

Price Growth

DNTH (@Biotechnology) experienced а +3.97% price change this week, while ZVRA (@Biotechnology) price change was +1.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ZVRA is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($606M) has a higher market cap than ZVRA($533M). ZVRA YTD gains are higher at: 12.830 vs. DNTH (-13.532). ZVRA has higher annual earnings (EBITDA): -60.3M vs. DNTH (-116.76M). DNTH has more cash in the bank: 263M vs. ZVRA (62.6M). DNTH has less debt than ZVRA: DNTH (1.4M) vs ZVRA (61.8M). ZVRA has higher revenues than DNTH: ZVRA (40.6M) vs DNTH (6.52M).
DNTHZVRADNTH / ZVRA
Capitalization606M533M114%
EBITDA-116.76M-60.3M194%
Gain YTD-13.53212.830-105%
P/E Ratio3.24N/A-
Revenue6.52M40.6M16%
Total Cash263M62.6M420%
Total Debt1.4M61.8M2%
FUNDAMENTALS RATINGS
DNTH vs ZVRA: Fundamental Ratings
DNTH
ZVRA
OUTLOOK RATING
1..100
5074
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
6165
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
6038
P/E GROWTH RATING
1..100
7026
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (51) in the null industry is somewhat better than the same rating for ZVRA (84). This means that DNTH’s stock grew somewhat faster than ZVRA’s over the last 12 months.

DNTH's Profit vs Risk Rating (61) in the null industry is in the same range as ZVRA (65). This means that DNTH’s stock grew similarly to ZVRA’s over the last 12 months.

DNTH's SMR Rating (95) in the null industry is in the same range as ZVRA (99). This means that DNTH’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Price Growth Rating (38) in the null industry is in the same range as DNTH (60). This means that ZVRA’s stock grew similarly to DNTH’s over the last 12 months.

ZVRA's P/E Growth Rating (26) in the null industry is somewhat better than the same rating for DNTH (70). This means that ZVRA’s stock grew somewhat faster than DNTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHZVRA
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
84%
Bullish Trend 5 days ago
85%
Momentum
ODDS (%)
Bullish Trend 5 days ago
88%
Bullish Trend 5 days ago
78%
MACD
ODDS (%)
Bullish Trend 5 days ago
83%
Bearish Trend 5 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
79%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SWLSX39.030.49
+1.27%
Schwab Large-Cap Growth
POLIX48.710.60
+1.25%
Polen Growth Institutional
GLCCX21.480.24
+1.13%
Goldman Sachs Large Cap Gr Insghts C
LHCCX17.540.04
+0.23%
Lord Abbett Health Care C
EPDPX11.67-0.01
-0.09%
EuroPac International Dividend Income A

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+2.56%
IMNM - DNTH
52%
Loosely correlated
+2.43%
ERAS - DNTH
50%
Loosely correlated
-0.69%
XNCR - DNTH
47%
Loosely correlated
+1.45%
SYRE - DNTH
47%
Loosely correlated
+1.68%
CRNX - DNTH
47%
Loosely correlated
+1.22%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with CRNX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
N/A
CRNX - ZVRA
40%
Loosely correlated
+1.22%
ATXS - ZVRA
39%
Loosely correlated
+1.40%
QURE - ZVRA
38%
Loosely correlated
+0.98%
DNTH - ZVRA
37%
Loosely correlated
+2.56%
ERAS - ZVRA
36%
Loosely correlated
-0.69%
More